Journal of Bioequivalence & Bioavailability

Design development and in-vitro evaluation of mouth dissolving films of Granisetron hydrochloride

3^rd World Congress Bioavailability & Bioequivalence

March 26-28, 2012 Marriott Hotel & Convention Centre, Hyderabad, India

Swapnil P. Mahajan and S. B. Patil

Posters: J Bioequiv Availab

Abstract:

M ethods to improve patient?s compliance have always attracted scientists towards the development of fancy oral drug delivery systems. Among them, mouth dissolving drug delivery systems have acquired an important position in the market by overcoming previously encountered administration problems. The main aim of present study is to develop a novel mouth dissolving tablet of Granisetron hydrochloride. It is an antiemetic drug used in both chemotherapy and radiotherapy induced emesis and belongs to BCS Class III which has oral bioavailability of 60% due to hepatic first pass metabolism. To overcome this drawback, the study was carried out to formulate and evaluate mouth dissolving tablet. The tablets were prepared by direct compression method using Emcosoy (soy-polysaccharide) as a novel superdisintegrant, microcrystalline cellulose as a diluent, talc as lubricant and aspartame as a sweetener. Drug-excipient interactions were investigated by DSC, FT-IR and isothermal stress testing. The results showed that there is no interaction. Satisfactory results were obtained when subjected to physico-chemical tests such as hardness, weight variation, thickness, surface pH, friability, drug content. Tablets were also subjected to in vitro drug release studies by using modified dissolution apparatus. The dissolution profile and disintegrating time were found to be satisfactory. It was found that the tablet disintegrates within 6 seconds. Hence it is concluded that the mouth dissolving tablet of Granisetron hydrochloride is the promising formulation that could improve the bioavailability of the drug and also provide immediate relief from emesis